IL6 and anemia (phenotype): Comprehensive evaluation in these physiologically relevant systems—including cytotoxic efficacy, persistence, cytokine secretion (e.g., IL-6), and safety (e.g., off-target effects, anemia, and bone loss)—is essential to substantiate the therapeutic potential suggested by our Jurkat data.